NO20092433L - Anvendelse av beta-laktamase - Google Patents

Anvendelse av beta-laktamase

Info

Publication number
NO20092433L
NO20092433L NO20092433A NO20092433A NO20092433L NO 20092433 L NO20092433 L NO 20092433L NO 20092433 A NO20092433 A NO 20092433A NO 20092433 A NO20092433 A NO 20092433A NO 20092433 L NO20092433 L NO 20092433L
Authority
NO
Norway
Prior art keywords
beta
lactamase
antibiotic
class
combination
Prior art date
Application number
NO20092433A
Other languages
English (en)
Norwegian (no)
Inventor
Pertti Koski
Tapio Korkolainen
Kristiina Raatesalmi
Original Assignee
Ipsat Therapies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsat Therapies Oy filed Critical Ipsat Therapies Oy
Publication of NO20092433L publication Critical patent/NO20092433L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20092433A 2006-11-28 2009-06-26 Anvendelse av beta-laktamase NO20092433L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20065757A FI119678B (fi) 2006-11-28 2006-11-28 Beta-laktamaasin käyttö
PCT/FI2007/050627 WO2008065247A1 (en) 2006-11-28 2007-11-21 Use of beta-lactamase

Publications (1)

Publication Number Publication Date
NO20092433L true NO20092433L (no) 2009-06-26

Family

ID=37482569

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092433A NO20092433L (no) 2006-11-28 2009-06-26 Anvendelse av beta-laktamase

Country Status (12)

Country Link
US (1) US20090311234A1 (pt)
EP (1) EP2086570A1 (pt)
JP (1) JP2010511020A (pt)
KR (1) KR20090085122A (pt)
CN (1) CN101563099A (pt)
AU (1) AU2007327472A1 (pt)
BR (1) BRPI0718880A2 (pt)
CA (1) CA2670440A1 (pt)
FI (1) FI119678B (pt)
NO (1) NO20092433L (pt)
RU (1) RU2009124460A (pt)
WO (1) WO2008065247A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014201082B2 (en) * 2010-05-24 2015-04-30 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
FI20105572A0 (fi) * 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
EA028342B1 (ru) 2011-09-09 2017-11-30 Мерк Шарп И Доум Корп. Способы лечения пневмонии
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US20140274994A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Stabilizing ceftolozane
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274996A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Tazobactam and ceftolozane antibiotic compositions
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
EP3132033B1 (en) 2014-04-17 2019-10-30 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
JP6803328B2 (ja) * 2014-08-28 2021-01-06 シンセティック バイオロジクス，インコーポレイテッド 大腸菌ベースでのベータラクタマーゼ生産
JP6672277B2 (ja) 2014-10-08 2020-04-01 シンセティック・バイオロジクス・インコーポレイテッド ベータラクタマーゼ製剤およびその使用
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
CN107530406B (zh) 2015-02-23 2021-10-22 合成生物制品有限公司 用于保护肠微生物群系的与抗生素一起使用的碳青霉烯酶
AU2016229976B2 (en) 2015-03-06 2021-11-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
EP3474885B8 (en) * 2016-06-28 2023-06-21 Theriva Biologics, Inc. Microbiome protection from oral antibiotics
CN111511368B (zh) * 2017-12-25 2023-05-09 湘北威尔曼制药股份有限公司 治疗耐药性鲍曼不动杆菌感染的含哌拉西林钠和舒巴坦钠的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843302B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
CN101257892B (zh) * 2005-05-18 2013-01-02 达沃尔泰拉公司 吸附剂的结肠递送

Also Published As

Publication number Publication date
CA2670440A1 (en) 2008-06-05
EP2086570A1 (en) 2009-08-12
FI119678B (fi) 2009-02-13
WO2008065247A1 (en) 2008-06-05
US20090311234A1 (en) 2009-12-17
BRPI0718880A2 (pt) 2013-12-17
RU2009124460A (ru) 2011-01-10
AU2007327472A1 (en) 2008-06-05
CN101563099A (zh) 2009-10-21
JP2010511020A (ja) 2010-04-08
KR20090085122A (ko) 2009-08-06
FI20065757A (fi) 2008-05-29
FI20065757A0 (fi) 2006-11-28

Similar Documents

Publication Publication Date Title
NO20092433L (no) Anvendelse av beta-laktamase
MX2010007823A (es) Inhibidores de beta-lactamasa.
MX2009010946A (es) Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
ATE509917T1 (de) Gamma-secretase-inhibitoren
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
SG179418A1 (en) Inhibitors of the hedgehog pathway
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
EP2143443A4 (en) COMBINED USE OF A DIPEPTIDYL PEPTIDASE IV INHIBITOR COMPOUND AND A SWEETENER
GEP20135791B (en) Use of dipeptidyl peptidase inhibitors
WO2007115821A3 (en) Organic compounds
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
UA101943C2 (ru) Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
EP1740183B8 (en) Novel use for pde5 inhibitors
TW200716104A (en) Tricyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
EA201200823A1 (ru) Гетероциклические производные сульфонамидов
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
EA200701366A1 (ru) Кислородсодержащие аннелированные фенилпиперазин- и фенилдиазепанкарбоксамиды
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
EA200802136A1 (ru) Лечение меланомы
RU2006145753A (ru) Средство для лечения инфекционных болезней, вызванных множественно-устойчивыми бактериями

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application